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Summary
Two methods of administration of ipratropium bromide
(Atrovent; Boehringer Ingelheim) to wheezing children'< 25
months of age were compared: (I) the conventional nebulisa-
tion (15 children); and (iI) a metered-dose aerosol plus spacer
and mask (MDA group, 17 children). The drug induced a
significant and similar fall in respiratory rate in both groups.
Transcutaneous carbon dioxide pressure was also reduced
significantly but was more marked in the MDA group. This
increase in alveolar ventilation was 'similar in those < 12
months as in older children; in those with recurrent or with
first time wheezing; and in those with radiological evidence of
pneumonia. Clinical assessment of bronchospasm and reces-
sion was recorded as improved' in over 80% of both groups.
The MDA delivery of ipratropium bromide was as effective as
nebulisation and was more convenient, since it required less
time and equipment. It was also well accepted by the small
patients.
S Atr Med J 1991; 79: 536-538.
Wheezing is common in infants and toddlers. Hyperactive
airways may be secondary to respiratory infections, including
bronchiolitis, or to asthma. The therapeutic dilemma is twofold:
what drugs are helpful, and by what route should they be
administered. Nebulisation is a safe and effective means of
delivery but .B2-agonist bronchodilators have minimal effect on
clinical features or lung function until the patient is 18 - 20
months. 1,2
However, an anti-cholinergic drug, ipratropium bromide
(Atrovent; Boehringer IngeIheim), when nebulised in a dose of
250 J.l.g improved lung function in 40% of wheezing children,
many under the a~e ~~ trar and some of w:lOm wh.eezed
from acute bronchiolitIs.- The drug has a high maXllllUm
safe concentration so overdosage is not a hazard.
Recently, bronchodilators delivered to infants and children
via a metered-dose aerosol and spacer with face mask have
been shown to be effective.5- 7
This study was designed to confIrm the effIcacy of the
metered aerosol method compared with nebulisation of ipra-
tropium bromide when given to wheezing infants and toddlers.
The former method is convenient for primary health care
facilities or home use, since it does not depend upon the
availability of the nebuliser apparatus or a gas or electricity
source.
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Patients and methods
Children aged 3 - ~6 months were selected by medical officers
in an outpatients facility if they were wheezing and had
.recession, a respiratory rate> 6O/min at < 24 months and
> 50/min at > 24 months of age, and had not received a
bronchodilator in the previous 6 hours.
The children were allocated randomly to one of the following
treaunent regimens: (I) ipratropium bromide inhalant solution
250 J.l.g (I ml) in 2 ml of saline delivered by an electrically
driven nebuliser and a hand-held mask (NEB group); and (il)
ipratropium bromide metered-dose aerosol (20 J.l.glpuff), 10
puffs given over 2 - 3 minutes delivered through a face mask
anached to a spacer (MDA group) (Fig. I).
Both regimens were repeated after I hour and, if necessary,
further hourly doses were given at the discretion of the
anending medical officer.
Fig. 1. Metered-dose aerosol administered with spacer and face
mask.
Observations (by F.P.) were recorded on admission to the
study and I hour after each dose: (a) clinical: (I) recession
grade I - intercostal and subcostal, recession grade II -
grade I plus tracheal tug and sternal recession; (il) wheezing
grade I - scanty and interminent, wheezing grade II -
constant and polyphonic; and (iil) pulse and respiratory rates.
(b) Transcutaneous carbon dioxide pressure (ptCo2) and oxygen
saturation (Sao2) measurements by guise oximetry (FasTrac,
Sensor Medics) were available for two-thirds of the patients
(standardisation of the apparatus was performed before appli-
cation to each patient).
Statistical methods. The paired l-test was employed for
comparisons between time intervals of each parameter. A two-
way analysis of variance was performed to establish differences
between groups, age and the interaction between group and
age. The effect of pneumonia and recurrence of wheezing was
tested by the four-fold test.
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Results
iir Family history of asthma present
+ See text for explanation.
Thiny-two children were studied (median age 6 months; only
I child> 20 months). The characteristics of the children are
sl\own in Table I. Just over half had a prior history of
wheezing, 22% had grade 11 (severe) bronchospasm, and 5 had
radiological pneumonic shadowing. There was no significant
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In the NEB group the mean values for the respiratory rate
before and after the drug were significantly different (P <
0,(02). The fall in respiratory rate in the NEB group (-18 ±
12%) and in the MDA group (-19 ± 12%) were significantly
differentfrom zero (P = 0,0001).
The mean values for Ptc02 before and after the drug were
significantly different in the MDA group (P < 0,05). A
significant fall in Ptc02 was induced both by nebulisation (-8
± 8%;P = 0,0118) and by MDA (-19 ± 14%; P = 0,(029),
the change being greater in the MDA patients (P = 0,0770).
A significant fall in pulse rate was restricted to the MDA
group (-8 ± 10%; P = 0,000I). The effect of the drug on 5a02
was minimal in both groups.
In the four parameters measured, the effect of the drug was
the same in children aged~ 12 months as those> 12 months.
Figs 2 and 3 show respiratory rate and PtCO2 expressed as
percentage change plotted against age: a decrease of :5>' 15%


































































Fig. 2. Percentage change in respiratory rate induced by ipra-




TABLE 11. EFFECT OF IPRATROPIUM BROMIDE ON
CLINICAL FEATURES





Mter 2 doses of ipratropium bromide all but 3 children
were considered well enough by their physicians to go home.
One child in each group had an extra dose before discharge
and I child in the MDA group required admission to hospital
despite 4 doses.
Where clinical features of bronchospasm and recession
changed from grade I or 11 to a better grade, improvement
was documented (Table 11). In the total patient population
bronchospasm improved in 91% and recession in 81%, and
there were no differences between the two medication groups.
Table III shows the effect of the drug on all 32 children.
Mter 2 hours (in 3 patients after 3 - 4 hours) the mean values
for the respiratory rate had fallen significantly (P = 0,0001); as
had the Ptc02 (P = 0,0001) and pulse rate (P = 0,(071).
When the delivery systems were compared (Table IV) both
methods were shown to reduce the respiratory rate and Ptc02 .
Fig. 3. Percentage change in Ptc02 induced by ipratropium
bromide, related to age.
The fall in respiratory rate and Ptc02 was quantitatively the
same in children with recurrent compared with first-time-
wheezing, and in those with and without radiological
pneumonia.
Pulse rate (N = 32)
Respiratory rate (N = 32)
Sa02 (N= 22)
Ptc02 (N = 22)
TABLE Ill. EFFECT OF IPRATROPIUM BROMIDE ON TOTAL STUDY GROUP (MEAN ± SO)
Before After Change % change
136±20* 129±15* -7±13 -4±9
69±9** 56±11** -13±8 -18±12
93 ± 3 95 ± 2 1 ± 3 1 ± 3
38 ± 7*** 32 ± 7*** -5 ± 4 -13 ± 12
• P=0,OO71 .
•• P= 0,0001 .
••• P=0,0001.
t After 2 - 4 doses.
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In this study ipratropium bromide could be shown by simple
monitoring methods to benefit some wheezing infants < 25
months of age. Following administration there was a significant
fall in both respiratory rate and PtC02 (P = 0,00(1). Since
arterial (and therefore Ptco2) and alveolar carbon dioxide
pressures are linearly related, the fall in PtC02 reflected an
increased alveolar ventilation. This would follow either a rise
in respiratory frequency or an increase in tidal volume. The
first option did not occur. This improvement in alveolar
ventilation was significantly greater in the MDA group than in
the NEB group (P = 0,0370).
Meaningful benefit from the drug, if judged by a ;:;:,: 15%
decrease, occurred in the Ptco2 of 10 of 22 children (45%) and
in the respiratory rate in 56%. Further, children < 12 >
months reacted similarly (Figs 2 and 3), and the response w~s
not affected by the presence of radiological lower-respiratory
tract infection or a history of previous wheezing.
Sao2 was not altered by the drug and tachycardia was
reduced only in the MDA group (P = 0,(034).
In other studies of ipratropium bromide in bronchiolitics
and wheezing children < 3 years of age, work of breathing,
airway resistance and total respiratory resistance were improved
in 40% of cases, with response demonstrated in those < 1
year. 2,3 The mechanism of action is probably a decrease in
central airway resistance, while peripheral airway function is
unchanged.3,-
The clinical parameters of recession and bronchospasm were
judged to have improved in over 80% of children, with similar
results in both groups. This is a better clinical response than
reported previously in bronchiolitis and infantile asthma.8,9
Delivery of the drug by an MDA with spacer and face mask
produced effects comparable to the well-tried nebulisation
method, the mean improvement in alveolar ventilation in fact
being greater in the MDA group (P = 0,0370).
Our data can be added to those of more sophi'sticated
studies that conclude that ipratropium bromide benefits a
useful percentage of young children with hyperreactive airways.
Delivery of the drug via an MDA obviates the need for
expensive nebulisation apparatus and extends the use of this
treatment modality to primary health care facilities that would
normally not offer it. Substitution of a polystyrene cup for the
spacer and mask would permit continuation of treatment in
the home. The technique was easily mastered by mothers and
was well accepted by the infants.
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